Neuropace Inc - Asset Resilience Ratio
Neuropace Inc (NPCE) has an Asset Resilience Ratio of 39.64% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Neuropace Inc (NPCE) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Neuropace Inc's Asset Resilience Ratio has changed over time. See Neuropace Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Neuropace Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NPCE market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $39.20 Million | 39.64% |
| Total Liquid Assets | $39.20 Million | 39.64% |
Asset Resilience Insights
- Very High Liquidity: Neuropace Inc maintains exceptional liquid asset reserves at 39.64% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Neuropace Inc Industry Peers by Asset Resilience Ratio
Compare Neuropace Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
Annual Asset Resilience Ratio for Neuropace Inc (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Neuropace Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 37.29% | $39.37 Million | $105.56 Million | -4.26pp |
| 2024-12-31 | 41.55% | $39.33 Million | $94.65 Million | -3.41pp |
| 2023-12-31 | 44.96% | $48.40 Million | $107.65 Million | -17.09pp |
| 2022-12-31 | 62.05% | $70.80 Million | $114.11 Million | -10.12pp |
| 2021-12-31 | 72.17% | $96.40 Million | $133.56 Million | +51.28pp |
| 2020-12-31 | 20.89% | $11.69 Million | $55.95 Million | +16.30pp |
| 2019-12-31 | 4.59% | $969.00K | $21.09 Million | -- |
About Neuropace Inc
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable a… Read more